Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
S. Ahmadi, S. Lotfi, S. Afshari, P. Kumar & E. Ghasemi. (2021) CORAL: Monte Carlo based global QSAR modelling of Bruton tyrosine kinase inhibitors using hybrid descriptors. SAR and QSAR in Environmental Research 32:12, pages 1013-1031.
Read now
Read now
Alia Fahmy, Ashley M Hopkins, Michael J Sorich & Andrew Rowland. (2021) Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature. Expert Opinion on Drug Metabolism & Toxicology 17:7, pages 803-821.
Read now
Read now
Articles from other publishers (45)
Hannah R. Wardill, Luke T. Wooley, Olivia M. Bellas, Katrina Cao, Courtney B. Cross, Madele van Dyk, Ganessan Kichenadasse, Joanne M. Bowen, Andrew C. W. Zannettino, Sepehr Shakib, Gregory B. Crawford, Jaroslav Boublik, Mellar M. Davis, Scott D. Smid & Timothy J. Price. (2023) Supporting gut health with medicinal cannabis in people with advanced cancer: potential benefits and challenges. British Journal of Cancer.
Crossref
Crossref
Suhrud Pathak, Kelsee K. Zajac, Manjusha Annaji, Manoj Govindarajulu, Rishi M. Nadar, Dylan Bowen, R. Jayachandra Babu & Muralikrishnan Dhanasekaran. (2023) Clinical outcomes of chemotherapy in cancer patients with different ethnicities. Cancer Reports 6:S1.
Crossref
Crossref
John O. Miners, Thomas M. Polasek, Julie-Ann Hulin, Andrew Rowland & Robyn Meech. (2023) Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance. Pharmacology & Therapeutics 248, pages 108459.
Crossref
Crossref
Jason van Leuven, Simon Evans, Ganessan Kichenadasse, Neeltje Steeghs, Billie Bonevski, Gerd Mikus & Madelé van Dyk. (2023) Framework for Implementing Individualised Dosing of Anti-Cancer Drugs in Routine Care: Overcoming the Logistical Challenges. Cancers 15:13, pages 3293.
Crossref
Crossref
Chiara Ghezzi, Stefani Perez, Kaitlin Ryan, Alicia Wong, Bao Ying Chen, Robert Damoiseaux & Peter M. Clark. (2022) Early Reduction of Glucose Consumption Is a Biomarker of Kinase Inhibitor Efficacy Which Can Be Reversed with GLUT1 Overexpression in Lung Cancer Cells. Molecular Imaging and Biology 25:3, pages 541-553.
Crossref
Crossref
Ashley M. Hopkins, Michael J. Sorich, Andrew J. McLachlan, Christos S. Karapetis, John O. Miners, Madelé van Dyk & Andrew Rowland. (2023) Understanding the Risk of Drug Interactions Between Ritonavir-Containing COVID-19 Therapies and Small-Molecule Kinase Inhibitors in Patients With Cancer. JCO Precision Oncology:7.
Crossref
Crossref
Sven Stegemann, Chris Moreton, Sami Svanbäck, Karl Box, Geneviève Motte & Amrit Paudel. (2022) Trends in oral small-molecule drug discovery and product development based on product launches before and after the Rule of Five. Drug Discovery Today, pages 103344.
Crossref
Crossref
Xueru He, Ying Li, Yinling Ma, Yuhao Fu, Xuejiao Xun, Yanjun Cui & Zhanjun Dong. (2022) Development of UPLC-MS/MS Method to Study the Pharmacokinetic Interaction between Sorafenib and Dapagliflozin in Rats. Molecules 27:19, pages 6190.
Crossref
Crossref
Yuji MukaiAzusa WakamotoTae HatsuyamaTatsunari YoshidaHideki SatoAkihisa Fujita, Nobuo InotsumeTakaki Toda. (2021) An Liquid Chromatography–Tandem Mass Spectrometry Method for the Simultaneous Determination of Afatinib, Alectinib, Ceritinib, Crizotinib, Dacomitinib, Erlotinib, Gefitinib, and Osimertinib in Human Serum. Therapeutic Drug Monitoring 43:6, pages 772-779.
Crossref
Crossref
Alessandro Parodi, Polina Buzaeva, Daria Nigovora, Alexey Baldin, Dmitry Kostyushev, Vladimir Chulanov, Lyudmila V. Savvateeva & Andrey A. ZamyatninJrJr. (2021) Nanomedicine for increasing the oral bioavailability of cancer treatments. Journal of Nanobiotechnology 19:1.
Crossref
Crossref
Murugaiah A. M. Subbaiah & Nicholas A. Meanwell. (2021) Bioisosteres of the Phenyl Ring: Recent Strategic Applications in Lead Optimization and Drug Design. Journal of Medicinal Chemistry 64:19, pages 14046-14128.
Crossref
Crossref
He Yu & Raj K. Singh Badhan. (2021) The Pharmacokinetics of Gefitinib in a Chinese Cancer Population Group: A Virtual Clinical Trials Population Study. Journal of Pharmaceutical Sciences 110:10, pages 3507-3519.
Crossref
Crossref
Zhe Wang, Xiaoyu Wang, Zhen Wang, Yaqin Jia, Yuyi Feng, Lili Jiang, Yangliu Xia, Jun Cao & Yong Liu. (2021) In vitro inhibition of human UDP-glucuronosyltransferase (UGT) 1A1 by osimertinib, and prediction of in vivo drug-drug interactions. Toxicology Letters 348, pages 10-17.
Crossref
Crossref
Omer Bayazeid & Taufiq Rahman. (2021) Correlation Analysis of Target Selectivity and Side Effects of FDA‐Approved Kinase Inhibitors**. ChemistrySelect 6:30, pages 7799-7814.
Crossref
Crossref
Madelé van Dyk, Norma Bulamu, Chelsea Boylan, Anna M Mc Laughlin, Ganessan Kichenadasse, Nikki May, Robin Michelet, Charlotte Kloft & Billingsley Kaambwa. (2021) Cost-effectiveness of oral anticancer drugs and associated individualised dosing approaches in patients with cancer: protocol for a systematic review. BMJ Open 11:8, pages e047173.
Crossref
Crossref
Carole Bandiera, Evelina Cardoso, Isabella Locatelli, Antonia Digklia, Khalil Zaman, Antonella Diciolla, Valérie Cristina, Athina Stravodimou, Aedo Lopez Veronica, Ana Dolcan, Apostolos Sarivalasis, Aikaterini Liapi, Hasna Bouchaab, Angela Orcurto, Jennifer Dotta-Celio, Solange Peters, Laurent Decosterd, Nicolas Widmer, Dorothea Wagner, Chantal Csajka & Marie Paule Schneider. (2021) Optimizing Oral Targeted Anticancer Therapies Study for Patients With Solid Cancer: Protocol for a Randomized Controlled Medication Adherence Program Along With Systematic Collection and Modeling of Pharmacokinetic and Pharmacodynamic Data. JMIR Research Protocols 10:6, pages e30090.
Crossref
Crossref
Yuji MukaiYuka YoshidaTatsunari YoshidaTakeshi Kondo, Nobuo InotsumeTakaki Toda. (2021) Simultaneous Quantification of BCR-ABL and Bruton Tyrosine Kinase Inhibitors in Dried Plasma Spots and Its Application to Clinical Sample Analysis. Therapeutic Drug Monitoring 43:3, pages 386-393.
Crossref
Crossref
Warit Ruanglertboon, Michael J. Sorich, Ashley M. Hopkins & Andrew Rowland. (2021) Mechanistic Modelling Identifies and Addresses the Risks of Empiric Concentration-Guided Sorafenib Dosing. Pharmaceuticals 14:5, pages 389.
Crossref
Crossref
Lauren A. Newman, Michael J. Sorich & Andrew Rowland. (2020) Role of Extracellular Vesicles in the Pathophysiology, Diagnosis and Tracking of Non-Alcoholic Fatty Liver Disease. Journal of Clinical Medicine 9:7, pages 2032.
Crossref
Crossref
Zhe Wang, Xiaoyu Wang, Yaqin Jia, Hang Yin, Yuyi Feng, Lili Jiang, Jun Cao & Yong Liu. (2020) Inhibition of human UDP‐glucuronosyltransferase enzymes by midostaurin and ruxolitinib: implications for drug–drug interactions. Biopharmaceutics & Drug Disposition 41:6, pages 231-238.
Crossref
Crossref
Michael D. Coleman. 2020. Human Drug Metabolism. Human Drug Metabolism
531
569
.
Evelina CardosoMonia GuidiBenoît Blanchet, Marie Paule SchneiderLaurent A. DecosterdThierry BuclinChantal CsajkaNicolas Widmer. (2020) Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review. Therapeutic Drug Monitoring 42:1, pages 33-44.
Crossref
Crossref
Pitsiree Praphanwittaya, Phennapha Saokham, Phatsawee Jansook & Thorsteinn Loftsson. (2020) Aqueous solubility of kinase inhibitors: I the effect of hydrophilic polymers on their γ-cyclodextrin solubilization. Journal of Drug Delivery Science and Technology 55, pages 101462.
Crossref
Crossref
Dakota Gustafson, Jason E. Fish, Jeffrey H. Lipton & Nazanin Aghel. (2020) Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia. Current Hematologic Malignancy Reports 15:1, pages 20-30.
Crossref
Crossref
Jeffry Adiwidjaja, Alan V. Boddy & Andrew J. McLachlan. (2020) Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics. Frontiers in Pharmacology 10.
Crossref
Crossref
Yuji Mukai, Tatsunari Yoshida, Takeshi Kondo, Nobuo Inotsume & Takaki Toda. (2020) Novel high-performance liquid chromatography–tandem mass spectrometry method for simultaneous quantification of BCR-ABL and Bruton’s tyrosine kinase inhibitors and their three active metabolites in human plasma. Journal of Chromatography B 1137, pages 121928.
Crossref
Crossref
Porntipa Korprasertthaworn, Nuy Chau, Pramod C. Nair, Andrew Rowland & John O. Miners. (2019) Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by kinase inhibitors: Effects of dabrafenib, ibrutinib, nintedanib, trametinib and BIBF 1202. Biochemical Pharmacology 169, pages 113616.
Crossref
Crossref
Madelé van Dyk, Asha J. Kapetas, Ashley M. Hopkins, A. David Rodrigues, Manoli Vourvahis, Michael J. Sorich & Andrew Rowland. (2019) Validation of a 3-h Sampling Interval to Assess Variability in Cytochrome P450 3A Phenotype and the Impact of Induction and Mechanism-Based Inhibition Using Midazolam as a Probe Substrate. Frontiers in Pharmacology 10.
Crossref
Crossref
Madelé van Dyk, John O. Miners, Jean-Claude Marshall, Linda S. Wood, Ashley Hopkins, Michael J. Sorich & Andrew Rowland. (2019) Identification of the caffeine to trimethyluric acid ratio as a dietary biomarker to characterise variability in cytochrome P450 3A activity. European Journal of Clinical Pharmacology 75:9, pages 1211-1218.
Crossref
Crossref
Pramod C. Nair, Ross A. McKinnon & John O. Miners. (2019) Computational Prediction of the Site(s) of Metabolism and Binding Modes of Protein Kinase Inhibitors Metabolized by CYP3A4. Drug Metabolism and Disposition 47:6, pages 616-631.
Crossref
Crossref
Michael J. Sorich, Fayzah Mutlib, Madelé Dyk, Ashley M. Hopkins, Thomas M. Polasek, Jean‐Claude Marshall, A. David Rodrigues & Andrew Rowland. (2019) Use of Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Axitinib Exposure: A Fresh Approach to Precision Dosing in Oncology. The Journal of Clinical Pharmacology 59:6, pages 872-879.
Crossref
Crossref
Hywel D. Williams, Leigh Ford, Annabel Igonin, Zhenhua Shan, Paolo Botti, Michael M. Morgen, Guixian Hu, Colin W. Pouton, Peter J. Scammells, Christopher J.H. Porter & Hassan Benameur. (2019) Unlocking the full potential of lipid-based formulations using lipophilic salt/ionic liquid forms. Advanced Drug Delivery Reviews 142, pages 75-90.
Crossref
Crossref
Thomas M. Polasek, Carl M. J. Kirkpatrick & Amin Rostami-Hodjegan. (2019) Precision dosing to avoid adverse drug reactions. Therapeutic Advances in Drug Safety 10, pages 204209861989414.
Crossref
Crossref
Andrew Rowland, Madelé van Dyk, Ashley M. Hopkins, Reham Mounzer, Thomas M. Polasek, Amin Rostami-Hodjegan & Michael J. Sorich. (2018) Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Drug Exposure. Clinical Pharmacology & Therapeutics 104:6, pages 1219-1228.
Crossref
Crossref
Madelé van Dyk, Jean-Claude Marshall, Michael J Sorich, Linda S. Wood & Andrew Rowland. (2018) Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries. European Journal of Clinical Pharmacology 74:7, pages 913-920.
Crossref
Crossref
Evelina Cardoso, Thomas Mercier, Anna Dorothea Wagner, Krisztian Homicsko, Olivier Michielin, Kim Ellefsen-Lavoie, Laurène Cagnon, Manuel Diezi, Thierry Buclin, Nicolas Widmer, Chantal Csajka & Laurent Decosterd. (2018) Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B 1083, pages 124-136.
Crossref
Crossref
Holger Petri. (2018) Arzneimitteltherapiesicherheit: Metabolische Interaktionen der Proteinkinase-Inhibitoren. Deutsches Ärzteblatt Online.
Crossref
Crossref
Evelina Cardoso, Chantal Csajka, Marie P. Schneider & Nicolas Widmer. (2017) Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs. Clinical Pharmacokinetics 57:1, pages 1-6.
Crossref
Crossref
P. Gougis, J. Wassermann, J.P. Spano, N. Keynan, C. Funck-Brentano & J.E. Salem. (2017) Clinical pharmacology of anti-angiogenic drugs in oncology. Critical Reviews in Oncology/Hematology 119, pages 75-93.
Crossref
Crossref
PJ Caraballo, SJ Bielinski, JL St. Sauver & RM Weinshilboum. (2017) Electronic Medical Record-Integrated Pharmacogenomics and Related Clinical Decision Support Concepts. Clinical Pharmacology & Therapeutics 102:2, pages 254-264.
Crossref
Crossref
Josep Esteve Romero, Jaume Albiol Chiva, Juan Peris-Vicente & Enrique Ochoa-Aranda. (2017) Development and validation of a micellar liquid chromatographic method to determine three antitumorals in plasma. Bioanalysis 9:10, pages 799-812.
Crossref
Crossref
John O. Miners, Nuy Chau, Andrew Rowland, Kushari Burns, Ross A. McKinnon, Peter I. Mackenzie, Geoffrey T. Tucker, Kathleen M. Knights & Ganessan Kichenadasse. (2017) Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia. Biochemical Pharmacology 129, pages 85-95.
Crossref
Crossref
Angela Rowland, Arduino A. Mangoni, Ashley Hopkins, Michael J. Sorich & Andrew Rowland. (2016) Optimized Cocktail Phenotyping Study Protocol Using Physiological Based Pharmacokinetic Modeling and In silico Assessment of Metabolic Drug–Drug Interactions Involving Modafinil. Frontiers in Pharmacology 7.
Crossref
Crossref
Madelé van Dyk, John O Miners, Ganessan Kichenadasse, Ross A McKinnon & Andrew Rowland. (2016) A novel approach for the simultaneous quantification of 18 small molecule kinase inhibitors in human plasma: A platform for optimised KI dosing. Journal of Chromatography B 1033-1034, pages 17-26.
Crossref
Crossref
Xueru He, Ying Li, Yinling Ma, Yuhao Fu, Xuejiao Xun, Yanjun Cui & Zhanjun Dong. (2022) Simultaneous Determination of Sorafenib and Dapagliflozin in Rat Plasma by UPLC MS-MS Method with Application in Pharmacokinetic Interactions Study. SSRN Electronic Journal.
Crossref
Crossref